Researchers investigated NAD concentration as a biomarker for personalizing nicotinamide mononucleotide (NMN) supplementation in humans. The study examined whether baseline NAD levels could predict individual responses to NMN treatment, potentially allowing tailored dosing strategies. This is human clinical evidence exploring the biological basis for individualized supplement approaches.